Literature DB >> 29427733

Extraesophageal Symptoms and Diseases Attributed to GERD: Where is the Pendulum Swinging Now?

Michael F Vaezi1, David Katzka2, Frank Zerbib3.   

Abstract

The purpose of this review is to outline the recent developments in the field of extraesophageal reflux disease and provide clinically relevant recommendations. The recommendations outlined in this review are based on expert opinion and on relevant publications from PubMed and EMbase. The Clinical Practice Updates Committee of the American Gastroenterological Association proposes the following recommendations: Best Practice Advice 1: The role of a gastroenterologist in patients referred for evaluation of suspected extra esophageal symptom is to assess for gastroesophageal etiologies that could contribute to the presenting symptoms. Best Practice Advice 2: Non-GI evaluations by ENT, pulmonary and/or allergy are essential and often should be performed initially in most patients as the cause of the extraesophageal symptom is commonly multifactorial or not esophageal in origin. Best Practice Advice 3: Empiric therapy with aggressive acid suppression for 6-8 weeks with special focus on response of the extraesophageal symptoms can help in assessing association between reflux and extraesophageal symptoms. Best Practice Advice 4: No single testing methodology exists to definitively identify reflux as the etiology for the suspected extra esophageal symptoms. Best Practice Advice 5: Constellation of patient presentation, diagnostic test results and response to therapy should be employed in the determination of reflux as a possible etiology in extra esophageal symptoms. Best Practice Advice 6: Testing may need to be off or on proton pump inhibitor (PPI) therapy depending on patients' presenting demographics and symptoms in assessing the likelihood of abnormal gastroesophageal reflux. A. On therapy testing may be considered in those with high probability of baseline reflux (those with previous esophagitis, Barrett's esophagus or abnormal pH). B. Off therapy testing may be considered in those with low probability of baseline reflux with the goal of identifying moderate to severe reflux at baseline. Best Practice Advice 7: Lack of response to aggressive acid suppressive therapy combined with normal pH testing off therapy or impedance-pH testing on therapy significantly reduces the likelihood that reflux is a contributing etiology in presenting extraesophageal symptoms. Best Practice Advice 8: Surgical fundoplication is discouraged in those with extra esophageal reflux symptoms unresponsive to aggressive PPI therapy. Best Practice Advice 9: Fundoplication should only be considered in those with a mechanical defect (e.g., hiatal hernia), moderate to severe reflux at baseline off PPI therapy who have continued reflux despite PPI therapy and have failed more conservative non-GI treatments.
Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Asthma; Cough; Laryngitis; Reflux Testing and Treatment

Mesh:

Year:  2018        PMID: 29427733     DOI: 10.1016/j.cgh.2018.02.001

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  9 in total

Review 1.  Advances in the Diagnosis and Treatment of GERD: New Tricks for an Old Disease.

Authors:  Rishi D Naik; Lauren Evers; Michael F Vaezi
Journal:  Curr Treat Options Gastroenterol       Date:  2019-03

2.  Upper Endoscopy in Patients with Extra-Oesophageal Reflux Symptoms: A Multicentre Study.

Authors:  Angelo Zullo; Giulia Fiorini; Gabrio Bassotti; Francesco Bachetti; Fabio Monica; Daniele Macor; Omero Alessandro Paoluzi; Giuseppe Scaccianoce; Piero Portincasa; Vincenzo De Francesco; Roberto Lorenzetti; Ilaria Maria Saracino; Matteo Pavoni; Dino Vaira
Journal:  GE Port J Gastroenterol       Date:  2020-02-04

Review 3.  Chronic cough in adults: recommendations from an Italian intersociety consensus.

Authors:  Antonio De Vincentis; Fabio Baldi; Massimo Calderazzo; Umberto Caliceti; Gabriella Guarnieri; Francesco Lombardi; Francesco Paolo Lombardo; Stefania Maggi; Graziano Onder; Adriano Vaghi; Alessandro Zanasi; Raffaele Antonelli Incalzi
Journal:  Aging Clin Exp Res       Date:  2022-06-06       Impact factor: 3.636

Review 4.  An update on current treatment strategies for laryngopharyngeal reflux symptoms.

Authors:  Amanda J Krause; Erin H Walsh; Philip A Weissbrod; Tiffany H Taft; Rena Yadlapati
Journal:  Ann N Y Acad Sci       Date:  2021-12-17       Impact factor: 6.499

5.  Insights on Extraesophageal Gastroesophageal Reflux Disease.

Authors:  Anjana Sathyamurthy
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-02

6.  Washed microbiota transplantation reduces proton pump inhibitor dependency in nonerosive reflux disease.

Authors:  Ya-Mei Zheng; Xian-Yun Chen; Jie-Yi Cai; Yu Yuan; Wen-Rui Xie; Jia-Ting Xu; Harry Hua-Xiang Xia; Min Zhang; Xing-Xiang He; Li-Hao Wu
Journal:  World J Gastroenterol       Date:  2021-02-14       Impact factor: 5.742

Review 7.  Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021.

Authors:  Katsuhiko Iwakiri; Yasuhiro Fujiwara; Noriaki Manabe; Eikichi Ihara; Shiko Kuribayashi; Junichi Akiyama; Takashi Kondo; Hiroshi Yamashita; Norihisa Ishimura; Yuichi Kitasako; Katsunori Iijima; Tomoyuki Koike; Nobuo Omura; Tsutomu Nomura; Osamu Kawamura; Shuichi Ohara; Soji Ozawa; Yoshikazu Kinoshita; Satoshi Mochida; Nobuyuki Enomoto; Tooru Shimosegawa; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2022-02-28       Impact factor: 7.527

8.  Quantitative assessment of multichannel intraluminal impedance pH and its clinical implications.

Authors:  Eden Koo; John O Clarke; Boli Yang; Pankaj J Pasricha; Nina Zhang
Journal:  Physiol Rep       Date:  2022-02

9.  Efficacy of a high-dose proton pump inhibitor in patients with gastroesophageal reflux disease: a single center, randomized, open-label trial.

Authors:  Jae Ho Cho; Cheol Min Shin; Hyuk Yoon; Young Soo Park; Nayoung Kim; Dong Ho Lee
Journal:  BMC Gastroenterol       Date:  2020-08-18       Impact factor: 3.067

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.